Peri-operative SLOG for Localized Pancreatic Cancer

Inclusion Criteria

• •A. Localized resectable or potentially resectable pancreatic cancer as determined by image modality; resectability is determined by the treating surgeon No prior treatment for pancreatic cancer
• •B. Patients must agree to receive biopsy for histological diagnosis and provide residual tissue for biomarker analysis before chemotherapy
• •C. Patients must agree to provide tissue for biomarker analysis after neoadjuvant chemotherapy, either surgical specimen or follow-up biopsy in unsectable disease
• •D. At least one measurable lesion according to RECIST version 1.1
• •E. Ability to understand and willingness to sign a written informed consent document.
• •F. Eastern Cooperative Oncology Group (ECOG) performance status 0-1
• •G. Age of 20 years or above
• •H. Life expectancy of at least 12 weeks
• •I. Adequate organ function as defined by the following criteria:
• •absolute neutrophil count (ANC) ≥ 1,500/mm3
• •hemoglobin level ≥ 9 g/dL
• •platelet count ≥ 100,000/mm3
• •total bilirubin \< 2 mg/dL
• •aspartate aminotransferase (AST) / alanine aminotransferase (ALT) ≤ 3 x upper limit of normal (ULN)
• •creatinine clearance rate (CCr) ≥ 50 mL/min (24-hour urine collection or calculated by Cockroft-Gault formula; male: \[(140 - age) × weight (kg)\]/\[72 × serum creatinine(mg/dL)\];female=male x 0.85
• •J. Patients with childbearing potential shall have effective contraception for both the patient and his or her partner during the study.